Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
619 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 1Taking peopleA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 194
- Run by
- Hefei TG ImmunoPharma Co., Ltd.
See details and how to joinNCT07376707 - Phase 3Taking peopleA Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 604
- Run by
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07229625 - No phaseNot yet taking people in ChinaA Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma
- Where
- Ningbo
- Age
- 16 years and over
- People
- 300
- Run by
- Ningbo Medical Center Lihuili Hospital
See details and how to joinNCT07368023 - Phase 1Taking peopleFirst in Human Study of SIM0610 in Solid Tumors
- Where
- Chongqing, Harbin, Jinan, Shanghai, Shenyang
- Age
- 18 years and over
- People
- 260
- Run by
- Jiangsu Simcere Pharmaceutical Co., Ltd.
See details and how to joinNCT07348211 - Phase 2Not yet taking people in ChinaDrug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 56
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07363356 - Phase 1Taking peopleA Phase I Study of CREPT-618 in Locally Advanced HCC
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 13
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07364357 - No phaseTaking peopleA Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 12
- Run by
- Zhejiang University
See details and how to joinNCT07039201 - No phaseTaking peopleLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Where
- Hangzhou
- People
- 1,200
- Run by
- Zhejiang University
See details and how to joinNCT07359586 - Phase 1Taking peopleA Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
- Where
- Hangzhou, Zhengzhou
- Age
- 18 years to 75 years
- People
- 72
- Run by
- Zhejiang University
See details and how to joinNCT05155189 - Early phase 1Taking peopleTC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT07242417 - Phase 3Not yet taking people in ChinaNanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
- Where
- Chengdu
- Age
- 18 years to 85 years
- People
- 68
- Run by
- Changchun GeneScience Pharmaceutical Co., Ltd.
See details and how to joinNCT07356037 - No phaseTaking peopleClinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
- Where
- Anyang, Beijing, Ganzhou, Gongzhuling, Guiyang, Hefei, Lishui, Luoyang, Nanchang, Nanning, Shijiazhuang, Taiyuan, Wenzhou, Yichang, Zhengzhou
- Age
- 18 years to 80 years
- People
- 216
- Run by
- JIANGSU SHENMING Medical Technology CO., Ltd
See details and how to joinNCT07356531 - Phase 2Not yet taking people in ChinaFAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years and over
- People
- 86
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07314372 - Phase 2Not yet taking people in ChinaTACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Where
- Fuzhou, Jinan, Nanning, Qingdao, Taihe, Wuhan
- Age
- 18 years to 75 years
- People
- 78
- Run by
- Tongji Hospital
See details and how to joinNCT07350070 - No phaseNot yet taking people in ChinaPredictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 276
- Run by
- Tongji Hospital
See details and how to joinNCT07350824 - Phase 2Not yet taking people in ChinaSintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 110
- Run by
- Lei ZHAO
See details and how to joinNCT07352007 - Early phase 1Not yet taking people in ChinaHead to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
- Where
- Wuhan
- Age
- 18 years and over
- People
- 150
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07352345 - Phase 2Not yet taking people in ChinaFOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Sun Yat-sen University
See details and how to joinNCT07353827 - Phase 2Taking peopleSintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 37
- Run by
- Sun Yat-sen University
See details and how to joinNCT07324824 - No phaseTaking peopleConversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
- Where
- Nanning
- Age
- 18 years to 75 years
- People
- 2,000
- Run by
- Guangxi Medical University
See details and how to joinNCT06405321 - Phase 2Taking peopleQL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 38
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07327788 - No phaseNot yet taking people in ChinaA Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 193
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07337031 - Phase 2Taking peopleEfcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
- Where
- Yangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07337421 - Phase 2Taking peopleEfficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
- Where
- Yangzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07337460 - Phase 2Not yet taking people in ChinaExploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 25
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07328802